Table 1.
Contrasting general statin intolerance with raised CK and statin tolerance (ST1) and low dose intolerance with statin tolerance (ST2)
| Variables | GSI |
P-value | LDI |
P-value | ||
|---|---|---|---|---|---|---|
| Cases (n = 588) | Controls (n = 356) | Cases (n = 591) | Controls (n = 443) | |||
| Mean age start therapy (SD) | 60 (10) | 62 (10) | 0.005 | 60 (10) | 60 (10) | 0.9 |
| Years on statin therapy (SD) | 10.4 (5) | 9.3 (3) | <0.0001 | 10 (5) | 9.5 (3) | 0.007 |
| Sex (% females) | 50 | 43 | 0.007 | 48 | 46 | 0.16 |
| Type 2 diabetics (%) | 78 | 79 | 0.68 | 92 | 90 | 0.33 |
| First statin as simvastatin (%) | 64 | 71 | <0.0001 | 59 | 65 | <0.0001 |
| Last statin as simvastatin (%) | 31 | 41 | <0.0001 | 31 | 36 | <0.0001 |
| Starting dose as ‘low’ (<20 mg/day) (%) | 85 | 53 | <0.0001 | 94 | 37 | <0.0001 |
| Ending dose as ‘high’ (≥80 mg/day) (%) | 22 | 36 | <0.0001 | 23 | 50 | <0.0001 |
| Interacting co-medications (yes %) | 52 | 44 | 0.0025 | 51% | 42% | <0.0001 |
| Statin use for secondary prevention of CVD (%) | 27 | 23 | 0.18 | 28% | 25% | 0.3 |
| CK levels (IU/L)a | ||||||
| Median | 200 | 76 | <0.0001 | 98 | 85 | <0.0001 |
| Mean (minimum, maximum) | 306 (120, 12, 700) | 81 (17, 179) | 170 (13, 12 735) | 107 (19, 1369) | ||
| LDL levels (mmol/L)a | ||||||
| Median | 3.5 | 3.2 | 0.07 | 3.2 | 3.1 | 0.38 |
| Mean (minimum, maximum) | (3.5) (1.1, 5.5) | 3.2 (0.4, 8.7) | 3.1 (1.1, 6.4) | 3.2 (0.5, 8.7) | ||
a
Indicates associations were tested using log 10 transformed values.
SD, standard deviation; GSI, general statin intolerance; LDI, Low dose intolerance.